Showing results (1-10 of 70) with videos related to
Sort By:
Pageof 7
Journal of Innate Immunity|March 18, 2011
The bidirectional crosstalk between human dendritic cells and natural killer cellsRebekka Wehner, Kristin Dietze, Michael Bachmann, et al.Stem Cells and Development|October 15, 2009
Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disordersSenming Zhao, Rebekka Wehner, Martin Bornhäuser, et al.Clinical & Developmental Immunology|January 24, 2014
Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100Kai Naumann, Rebekka Wehner, Anett Schwarze, et al.European Journal of Immunology|February 2, 2022
Tumor-associated human dendritic cell subsets: Phenotype, functional orientation, and clinical relevanceIoana Plesca, Luise Müller, Jan P Böttcher, et al.Cancers|November 12, 2013
Tumor-associated antigens for specific immunotherapy of prostate cancerAndrea Kiessling, Rebekka Wehner, Susanne Füssel, et al.Pharmacological Research|August 27, 2018
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapyMarvin Kuske, Dana Westphal, Rebekka Wehner, et al.International Journal of Cancer|August 22, 2012
Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc+ (slan) dendritic cellsRebekka Wehner, Anna Bitterlich, Nicole Meyer, et al.Biomedicines|March 2, 2018
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor TreatmentAntje Tunger, Maximilian Kießler, Rebekka Wehner, et al.Journal of Biomedicine & Biotechnology|May 15, 2010
Chimeric antigen receptor-engineered T cells for immunotherapy of cancerMarc Cartellieri, Michael Bachmann, Anja Feldmann, et al.European Urology|December 7, 2007
Advances in specific immunotherapy for prostate cancerAndrea Kiessling, Susanne Füssel, Rebekka Wehner, et al.Pageof 7